AKT1 and neoplasm: Moreover, pretreatment with the RAS inhibitor salirasib (S-farnesylthiosalicylic acid, FTS) not only blocked PDE4DIP-promoted ERK/AKT phosphorylation but also nullified the promoting effect of PDE4DIP on tumor cell growth (Fig. 3E, F, Fig. S4B).